FindTrial
Sign In

Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina? - Allopurinol in normotensive patients with left ventricular hypertrophy

Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina? - Allopurinol in normotensive patients with left ventricular hypertrophy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-008479-32-GB
Enrollment
66
Registered
2009-01-15
Start date
2009-06-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular hypertrophy Normotensive Chronic stable angina MedDRA version: 9.1 Level: LLT Classification code 10049773 Term: Left ventricular hypertrophy MedDRA version: 9.1 Level: LLT Classification code 10049194 Term: Stable angina pectoris MedDRA version: 9.1 Level: LLT Classification code 10005754 Term: Blood pressure normal

Interventions

Trade Name: Allopurinol Product Name: Allopurinol Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Sponsors

University of Dundee
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Normotensive patients (SBP=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Suffers from gout Already on allopurinol treatment Previous adverse reaction to allopurinol Patient currently on azathioprine Renal dysfunction (eGFR < 60ml/min) Heart failure or LVEF <45% Contraindications to MRI such as metal implants in body and claustraphobia Cancer or lifethreatening illness Pregnancy or breastfeeding Unable to give informed consent

Design outcomes

Primary

MeasureTime frame
Secondary Objective: Does Allopurinol reduce endothelial dysfunction in normotensive patients with stable angina?;Primary end point(s): Left ventricular hypertrophy regression on cardiac MRI To see if allopurinol reduces endothelial dysfunction as assessed by flow mediated dilatation (FMD);Main Objective: Does Allopurinol reduce left ventricular hypertrophy in normotensive patients with stable angina?—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026